Luis Montuenga, MD, Clinica Universidad de Navarra, Pamplona, Spain, talks on the advances in genetic testing for actionable mutations, including in technologies that can provide multiple mutational analysis. The limitations of biomarker testing are additionally discussed, including the lack of accessibility to biomarker analysis for some patients. This interview took place during the virtual European Lung Cancer Congress 2022.